Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	8.95	14.7	4.34	1.83	3.52
Revenue Growth (YoY)	-39.16%	238.70%	137.73%	-48.05%	-29.53%
Cost of Revenue	0.67	0.73	1.43	0.39	0.41
Gross Profit	8.27	13.98	2.92	1.44	3.1
Selling, General & Admin	17.3	22.51	18.21	15.57	24.03
Research & Development	15.71	13.99	33.91	12.32	17.95
Operating Expenses	33.01	36.5	52.13	27.89	41.98
Operating Income	-24.73	-22.52	-49.21	-26.45	-38.88
Other Expense / Income	-1.44	3.21	-6.19	-4.56	-19.76
Pretax Income	-23.29	-25.73	-43.02	-21.89	-19.12
Income Tax	-1.8	0.54	0	-1.24	-7.41
Net Income	-21.49	-26.27	-43.02	-20.65	-11.71
Shares Outstanding (Basic)	173	170	165	150	146
Shares Outstanding (Diluted)	173	170	165	150	146
Shares Change	1.69%	3.22%	9.64%	3.10%	14.68%
EPS (Basic)	-0.12	-0.15	-0.26	-0.14	-0.08
EPS (Diluted)	-0.12	-0.15	-0.26	-0.14	-0.08
Free Cash Flow	-29.24	0.65	-23.9	-19.79	-32.31
Free Cash Flow Per Share	-0.17	0.00	-0.14	-0.13	-0.22
Gross Margin	92.50%	95.05%	67.15%	78.92%	88.28%
Operating Margin	-276.50%	-153.17%	-1133.63%	-1448.36%	-1106.00%
Profit Margin	-240.20%	-178.69%	-990.99%	-1130.83%	-333.12%
Free Cash Flow Margin	-326.89%	4.39%	-550.59%	-1084.01%	-919.06%
EBITDA	-22.6	-25.01	-42.15	-19.78	-15.99
EBITDA Margin	-252.62%	-170.07%	-970.88%	-1083.08%	-454.82%
Depreciation & Amortization	0.69	0.73	0.87	2.11	3.13
EBIT	-23.29	-25.73	-43.02	-21.89	-19.12
EBIT Margin	-260.36%	-175.01%	-990.99%	-1198.69%	-543.84%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).